Bio-Path Holdings Book Value 2011-2026 | BPTH

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Bio-Path Holdings

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
441 K	14.2 M	25.5 M	15.1 M	21.1 M	1.22 M	8.07 M	8.24 M	9.82 M	14.9 M	4.78 M	2.01 M	2.91 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
25.5 M	441 K	9.86 M

Quarterly Book Value Bio-Path Holdings

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-8 M	-7.16 M	-2.59 M	154 K	-712 K	1.29 M	-2.62 M	441 K	2.52 M	5.04 M	9.11 M	14.2 M	16.2 M	19.5 M	22.3 M	25.5 M	29.3 M	29.8 M	31.4 M	15.1 M	15.1 M	15.1 M	15.1 M	21.1 M	21.1 M	21.1 M	21.1 M	1.22 M	1.22 M	1.22 M	1.22 M	8.07 M	8.07 M	8.07 M	8.07 M	8.24 M	8.24 M	8.24 M	8.24 M	9.82 M	9.82 M	9.82 M	9.82 M	14.9 M	14.9 M	14.9 M	14.9 M	4.78 M	4.78 M	4.78 M	4.78 M	2.01 M	2.01 M	2.01 M	2.01 M	2.91 M	2.91 M	2.91 M	2.91 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
31.4 M	-8 M	9.12 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	76.6 M	$ 4.5	0.45 %	$ 862 M	Canada
ADC Therapeutics SA ADCT	88.7 M	$ 3.83	1.32 %	$ 105 M	Schweiz
Agenus AGEN	227 M	$ 3.64	9.31 %	$ 108 M	USA
Agios Pharmaceuticals AGIO	1.19 B	$ 35.08	-0.36 %	$ 2.03 B	USA
Akebia Therapeutics AKBA	32.6 M	$ 1.39	0.36 %	$ 357 M	USA
Akari Therapeutics, Plc AKTX	28.3 M	$ 3.95	-11.63 %	$ 266 B	Britain
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Aldeyra Therapeutics ALDX	44.3 M	$ 1.57	-5.42 %	$ 94.3 M	USA
Aligos Therapeutics ALGS	53.5 M	$ 8.08	1.38 %	$ 79.9 M	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Alnylam Pharmaceuticals ALNY	789 M	$ 331.14	3.85 %	$ 43.4 B	USA
Altimmune ALT	225 M	$ 3.4	1.8 %	$ 300 M	USA
ALX Oncology Holdings ALXO	26 M	$ 1.99	0.81 %	$ 107 M	USA
Amgen AMGN	90.6 B	$ 344.03	-1.12 %	$ 185 B	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Amneal Pharmaceuticals AMRX	3.68 B	$ 12.27	-1.68 %	$ 3.85 B	USA
Anika Therapeutics ANIK	271 M	$ 14.99	1.28 %	$ 220 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
ANI Pharmaceuticals ANIP	429 M	$ 73.8	-0.55 %	$ 1.43 B	USA
Annexon ANNX	212 M	$ 5.56	1.0 %	$ 862 M	USA
Annovis Bio ANVS	16.9 M	$ 2.56	12.28 %	$ 52.6 M	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Aptorum Group Limited APM	11.8 M	$ 0.88	-5.16 %	$ 4.8 M	China
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Aprea Therapeutics APRE	15.9 M	$ 0.7	-1.87 %	$ 4.58 M	USA
Aquestive Therapeutics AQST	-33.7 M	$ 4.12	-0.24 %	$ 441 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Arcturus Therapeutics Holdings ARCT	214 M	$ 8.14	1.31 %	$ 223 M	Israel
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Ardelyx ARDX	167 M	$ 5.99	0.84 %	$ 1.44 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
argenx SE ARGX	7.32 B	$ 749.99	0.48 %	$ 25 B	Niderland
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Arcutis Biotherapeutics ARQT	189 M	$ 24.06	1.82 %	$ 3.06 B	USA
Arvinas ARVN	434 M	$ 10.87	0.14 %	$ 771 M	USA
Arrowhead Pharmaceuticals ARWR	1.39 B	$ 60.28	-1.23 %	$ 8.06 B	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Assembly Biosciences ASMB	207 M	$ 29.51	1.72 %	$ 331 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	16.9 M	-	10.36 %	$ 9.8 M	USA
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.62	1.82 %	$ 8.71 B	Australia